• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Kenneth Ataga, MD

Division of Hematology/Oncology
University of Tennessee Health Science Center
956 Court Avenue
D324 Coleman Building
Memphis, Tennessee, United States

Dr. Ataga’s clinical interest is in classical hematology and hemoglobinopathies. He is the Director of the Center for Sickle Cell Disease at the University of Tennessee Health Science Center (UTHSC) at Memphis. His clinical research is focused on the vasculopathy of sickle cell disease, with an emphasis on pulmonary hypertension and renal complications, and coagulation activation in sickle cell disease. In addition, Dr. Ataga has a strong research interest in the development of new therapies for sickle cell disease. He conducts clinical trials in sickle cell disease funded by the National Institutes of Health and the Pharmaceutical Industry.


Representative Publications:

Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe

Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease

Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies

Albuminuria Is Associated with Endothelial Dysfunction and Elevated Plasma Endothelin-1 in Sickle Cell Anemia

Pharmacologic Therapies for Sickle Cell Disease

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.